The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang Province, China.
Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12423-12436. doi: 10.26355/eurrev_202012_24038.
To design and evaluate a novel oxyntomodulin (OXM) derivative with albumin-binding helix domain and dual GLP-1 receptor (GLP-1R) and glucagon receptor (GcgR) activation activity to achieve metabolize improvement on the diabetes-related complication.
Mutation (D-Ser2) on OXM was performed and then different helix albumin-binding domains were fused to the mutated OXM via a thrombin-cleavable linker to generate seven fusion peptides, named LM01-LM07. Seven LM peptides were synthesized and screened via in vitro receptor activation test, albumin binding measurement and protease cleavage assay to select potent candidate peptide for further in vivo study. Moreover, acute and chronic efficacy studies were conducted to evaluate the efficacy of selected candidate using db/db mice.
LM06, as selected OXM derivative, exhibited higher albumin-binding affinity, sustained-release efficiency and balanced activation activities on both GLP-1R and GcgR compared with other ones. Moreover, LM06 was demonstrated with improved hypoglycemic and insulinotropic abilities in receptor-deficient mice via activating GLP-1R. In addition, prolonged anti-diabetic efficacies of LM06 were demonstrated via hypoglycemic duration assay and OGTT in db/db mice. Further pharmacokinetic test of LM06 in both rats and monkeys identified improved half-life and other metabolic characteristics. Nevertheless, 8-week subcutaneously dosed LM06 in db/db mice achieved prominent efficacies on glucostasis, weight-lowering, pancreatic function and adipogenesis via activating GLP-1R and GcgR. Moreover, LM06 also could accelerate diabetic skin wound closure in combination with low-intensity ultrasound.
LM06, as a long-acting dual GLP-1R/GcgR agonist, exerts potential as a once-weekly therapeutic candidate against diabetes-related complication in combination with low-intensity ultrasound.
设计并评估一种新型的胰泌素(OXM)衍生物,该衍生物具有白蛋白结合螺旋结构域和双重 GLP-1 受体(GLP-1R)和胰高血糖素受体(GcgR)激活活性,以改善与糖尿病相关的并发症。
对 OXM 进行突变(D-Ser2),然后通过凝血酶可切割的接头将不同的螺旋白蛋白结合结构域融合到突变的 OXM 上,生成七种融合肽,命名为 LM01-LM07。合成了七种 LM 肽,并通过体外受体激活试验、白蛋白结合测量和蛋白酶切割试验进行筛选,以选择具有进一步体内研究潜力的有效候选肽。此外,使用 db/db 小鼠进行了急性和慢性疗效研究,以评估所选候选肽的疗效。
所选 OXM 衍生物 LM06 与其他肽相比,具有更高的白蛋白结合亲和力、持续释放效率和对 GLP-1R 和 GcgR 的平衡激活活性。此外,LM06 通过激活 GLP-1R 在受体缺陷型小鼠中表现出改善的降血糖和胰岛素促分泌作用。此外,通过低血糖持续时间测定和 db/db 小鼠的 OGTT 证明了 LM06 的延长抗糖尿病疗效。LM06 在大鼠和猴子中的药代动力学试验进一步确定了其半衰期和其他代谢特征的改善。然而,在 db/db 小鼠中,皮下给予 8 周的 LM06 通过激活 GLP-1R 和 GcgR,在葡萄糖稳态、体重减轻、胰腺功能和脂肪生成方面取得了显著疗效。此外,LM06 还可以与低强度超声联合加速糖尿病皮肤伤口愈合。
LM06 作为一种长效双重 GLP-1R/GcgR 激动剂,具有与低强度超声联合治疗与糖尿病相关的并发症的潜在应用价值。